Published data regarding the efficacy of novel antipsychotic agents yield information about responders and nonresponders. However, the literature offers clinicians little guidance about the patient hidden above the efficacy curve, the patient with an incomplete response. In this article the issue ofpartial response is considered. Four strategies to use with patients who continue to have psychotic symptoms or symptoms of comorbid illnesses are described. nonpharmacologic interventions, changing the dose, changing the agent, and combination therapy. Anecdotal case reports illustrate the challenge of treating patients with a partial response.
Get full access to this article
View all access options for this article.
References
1.
Addington, D., Addington, J., & Maticka-Tyndale, E. (1994). Specificity of the Calgary Depression Scale for Schizophrenia. Schizophrenia Research, 11, 239-244.
2.
Andreasen, N. C. (1983). The Scale for Assessment of Negative Symptoms (SANS). Iowa City: The University of Iowa.
3.
Andreasen, N. C. (1984). The Scalefor Assessment of Positive Symptoms (SAPS). Iowa City: The University of Iowa.
4.
Bodkin, J. A., Cohen, B. M., Salomon, M. S., Cannon, S. E., Zornberg, G. L., & Cole, J. O. (1996). Treatment of negative symptoms in schizophrenia and schizoaffective disorder by selegiline augmentation of antipsychotic medication, a pilot study examining the role of dopamine. The journal of Nervous and Mental Disease, 184, 295-301.
5.
Byerly, M. J., & Devane, C. L. (1996). Pharmacokinetics of clozapine and risperidone: A review of recent literature. Journal of Clinical Psychopharmacology, 16, 177-187.
6.
Casey, D. E. (1995). Motor and mental aspects of extrapyramidal symptoms. International Clinical Psychopharmacology, 10(Suppl. 3), 105-114.
7.
Chouinard, G., Ross-Canard, A., Annable, L., & Jones, B. D. (1980). The Extra Pyramidal Symptom Rating Scale. Canadian Journal of Neurological Sciences, 7, 233-233.
8.
Cohen, B. M., & Waternaux, C. (1993). Neuroleptic plasma levels: Limitations and values. In S. R. Marder, J. M. Davis, & P. G. Janicak (Eds.), Clinical use of neuroleptic plasma levels (pp. 1-15). Washington, DC: American Psychiatric Press.
9.
Dobson, D. J., McDougall, G., Busheikin, J., & Aldous, J. (1995). Effects of social skills training and social milieu treatment on symptoms of schizophrenia. Psychiatric Services, 46
10.
Hasegawa, M., Gutierrez-Esteinou, P., Way, L., & Meltzer, H. (1993) Relationship between clinical efficacy and clozapine concentrations in plasma in schizophrenia: Effect of smoking. journal of Clinical Psycbopharmacology, 13;383-390.
11.
Herz, M. I., & Melville, C. (1980). Relapse in Schizoprenia. American Journal of Psychiatry, 139(7).
12.
Hogarty, G. E., Anderson, C. M., Reiss, D. J., Kornblith, S. J., Greenwald, D. P., Ulrich, R. F., & Carter M., (1991). Family psychoeducation, social skills training, and maintenance chemotherapy in the aftercare treatment of schizophrenia. II. Twoyear effects of a controlled trial on relapse and adjustment. Archives of General Psychiatry, 48, 340-347.
13.
Janicak, P. G., & Davis, J. M. (1996). Antipsychotic dosing strategies in acute schizophrenia. International Clinical Psychopharmacology, 1l(Suppl. 2), 35-40.
14.
Johnson, D.A. (1990). Pharmacological treatment of patients with schizophreniza: Past and present problems and future therapy. Drugs, 39(4)481-488.
15.
Kay, S. R., Fiszbein, A., & Opler, L. (1987). The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophrenia Bulletin, 13, 261-276.
16.
Kronig, M.H., Hunne, R.A., Szymanski, S., et al. (1995). Plasma clozapine levels and clinical response for treatment refractory schizophrenic patients. American Journal of Psychiatry, 152;179-182.
17.
Mc Evoy, J. P., Hogarth, G. E., & Steingard, S. (1991). Optimal dose of neuroleptic in acute schizophrenia: A controlled study of the neuroleptic threshold and higher haloperidol dose. Archives of General Psychiatry, 48, 730-745.
18.
Miller, D., Fleming, F., Holman, T., & Perry, P. (1994). Clozapine concentrations as a predictor of clinical response: A follow up study. Journal of Psychiatry, 55 [Supply B]: 117-121.
19.
Overall, J. E., & Gorham, D. R. (1962). The Brief Psychiatric Rating Scale. Psychological Reports, 10, 700-812.
20.
Perry, P., Miller, D., Arndt, S., & Cadoret, R. (1991). Clozapine and norclozapine plasma concentrations and clinical response of treatment, refractory schizophrenic patients. American Journal of Psychiatry, 148;231-235.
21.
Potkin, S. G., Bera, R., Gulasekaram, B., et al. (1994). Plasma clozapine concentrations predict clinical response in treatment resistant schizophrenia.Journal of Clinical Psychiatry, 55 [Suppl B]: 133-138.
22.
Schooler, N. R., Keith, S. J., Sever, J. B., & Matthews, S. M. (1995). Maintenance treatment of schizophrenia: A review of dose reduction and family treatment strategies. Psychiatric Quarterly, 66(4) 279-292.
23.
Shriqui, C. L. (1995). Neuroleptic dosing and neuroleptic plasma levels in schizophrenia: Determining the optimal regimen. Canadian Journal of Psychiatry, 20(Suppl. 2), s38-s48.
24.
Silver, H., Kushnir, M., & Kaplan, A. (1996). Fluvoxamine augmentation in clozapineresistant schizophrenia: An open pilot study. Biol Psychiatry, 40, 671-674.
25.
Van Putten, T., & Marder, S. R. (1995). Clinical use of neuroleptic levels. In C. L. Shriqui, & H. A. Nasrallah (Eds.), Contemporary issues in the treatment of schizophrenia (pp. 435-456). Washington, DC: American Psychiatric Press.
26.
Weiden, P.J., Olfson, M. (1995). Cost of relapse in schizophrenia. Scbizoprenia Bulletin, 21(3): 419-429.
27.
Zubin, J., & Spring, B. (1977). Vulnerability a new view of schizophrenia. Journal of Abnormal Psychology, 26, 86-103.
